Abstract
Objective: The aim of the present study was to evaluate the effect of the glucagon-like peptide-1 analog liraglutide on weight loss in overweight and obese women with polycystic ovary syndrome (PCOS).Methods: In an observational study, 84 overweight or obese women with PCOS were treated with liraglutide. Baseline characteristics and weight changes at clinical follow-up were recorded. Main outcome measures were absolute and relative weight loss.Results: In overweight or obese women with PCOS treated with liraglutide for a minimum of 4 weeks, a mean weight loss of 9.0 kg (95% CI: 7.8–10.1, p < 0.0001) and a mean decrease in BMI of 3.2 kg/m2 (95% CI: 2.8–3.6, p < 0.0001) were found. A weight loss of more than 5 and 10% of baseline weight was seen in 81.7 and 32.9% of patients, respectively. The mean duration of treatment with liraglutide was 27.8 weeks (SD 19.2).Conclusion: Treatment with liraglutide in combination with metformin and lifestyle intervention resulted in a significant weight loss in overweight and obese women with PCOS, indicating that liraglutide may be an effective alternative for weight loss in this group of patients. However, larger placebo-controlled studies are needed to confirm this.
Highlights
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, with a reported prevalence of 6–15% depending on the population studied and the diagnostic criteria used [1,2,3]
In overweight or obese women with PCOS treated with liraglutide for a minimum of 4 weeks, a mean weight loss of 9.0 kg and a mean decrease in body mass index (BMI) of 3.2 kg/m2 were found
Treatment with liraglutide in combination with metformin and lifestyle intervention resulted in a significant weight loss in overweight and obese women with PCOS, indicating that liraglutide may be an effective alternative for weight loss in this group of patients
Summary
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age, with a reported prevalence of 6–15% depending on the population studied and the diagnostic criteria used [1,2,3]. A large proportion of women with PCOS are overweight or obese, in particular with abdominal obesity [5] They often have insulin resistance, compensatory hyperinsulinemia, impaired glucose tolerance, and a higher risk of type 2 diabetes [6,7,8]. Obesity-related insulin resistance and resulting hyperinsulinemia may cause a decreased sex-hormone binding globulin production and an increased ovarian androgen production, both of which contribute to the hyperandrogenism. This may form a vicious circle as hyperandrogenism may contribute to the insulin resistance by increasing free fatty acid flux to the liver and muscle through visceral lipolysis and, in addition, by altering muscle structure toward less insulin-sensitive muscle fibers [5]. PCOS is associated with dyslipidemia and endothelial dysfunction
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
